Patient recruitment in Phase III trial has surpassed 60% Trial is expanded to Israel with first clinical site at Tel Aviv Medical Center NESS ZIONA, Israel – Dec. 21, 2020 – Mapi Pharma Ltd., a fully integrated, late clinical stage biopharmaceutical company,...
Facility in the Jerusalem Har-Hotzim technology park is built at the highest GMP standards; capability to provide reliable supply of COVID-19 vaccines, if approved NESS ZIONA, Israel – Oct. 7, 2020 – Mapi Pharma Ltd., a fully integrated, late clinical stage...
NESS ZIONA, Israel, September 30, 2020 — Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today greets its partner, Zhejiang Jingxin Pharmaceutical Co Ltd. To our friends and partners at Jingxin Pharma,...
90% of relapsing remitting multiple sclerosis (RRMS) patients on GA Depot demonstrated no evidence of disease activity (NEDA) at four years Data suggest that GA Depot may also have potential as a primary progressive multiple sclerosis (PPMS) treatment NESS...
Mylan to invest an additional $20M in Mapi Pharma in support of continued progress on Phase 3 clinical studies NESS ZIONA, Israel, June 15, 2020 — Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today announced...
Ness Ziona, Israel, October 28, 2019 — Mapi Pharma Ltd. announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple sclerosis (RMS). Glatiramer acetate, the active material of Copaxone®, or... 